BayCom (NASDAQ:BCML) reported quarterly earnings of $0.38 per share. This is a 22.45 percent decrease over earnings of $0.49 per share from the same period last year.
Bristol Myers Squibb Announced Earlier., Investigational LPA1 Antagonist Reduces Rate Of Lung Function Decline In Progressive Pulmonary Fibrosis Cohort Of Phase 2 Study
Bristol Myers Squibb (NYSE:BMY) today announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist in patients with progressive
